ANIX

Anixa Biosciences, Inc. [ANIX] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

ANIX Stock Summary

Top 10 Correlated ETFs

ANIX


Top 10 Correlated Stocks

ANIX


In the News

11:32 10 Jun 2023 ANIX

Is Anixa Biosciences (ANIX) Outperforming Other Medical Stocks This Year?

Here is how ANIXA BIOSCIENCES INC (ANIX) and Intuitive Surgical, Inc. (ISRG) have performed compared to their sector so far this year.

07:13 10 Jun 2023 ANIX

Anixa: I Am More Bullish After Efficacy Data For Its Triple-Negative Breast Cancer Vaccine

Anixa: I Am More Bullish After Efficacy Data For Its Triple-Negative Breast Cancer Vaccine

12:55 10 Jun 2023 ANIX

Anixa (ANIX) Falls 25% Despite Positive Breast Cancer Study Data

Anixa Biosciences (ANIX) announces positive top-line data from its phase Ia study evaluating the safety of its breast cancer vaccine. However, the stock plunges 25% in the absence of efficacy reports.

10:32 10 Jun 2023 ANIX

What Makes ANIXA BIOSCIENCES INC (ANIX) a Good Fit for "Trend Investing"

ANIXA BIOSCIENCES INC (ANIX) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

08:30 10 Jun 2023 ANIX

Anixa Biosciences to Present at the H.C. Wainwright 24th Annual Global Investment Conference

SAN JOSE, Calif. , Aug. 31, 2022 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today announced that it will present a company update at the H.C.

01:38 10 Jun 2023 ANIX

Anixa: Making Sense Of A Bullish Move Up In Bearish Biotech Times

Anixa Biosciences has different very interesting programs ongoing, one of which is a breast cancer vaccine trial with a first partial readout at ASCO in the beginning of June. While the biotech sector has been suffering large losses over the past month, Anixa Biosciences shares have moved up remarkably.

11:18 10 Jun 2023 ANIX

Has Anixa Biosciences (ANIX) Outpaced Other Medical Stocks This Year?

Here is how ANIXA BIOSCIENCES INC (ANIX) and Adherex Technologies Inc. (FENC) have performed compared to their sector so far this year.

09:05 10 Jun 2023 ANIX

Anixa (ANIX) COVID Compounds Prove Effective Against Omicron

Anixa Biosciences' (ANIX) potential COVID-19 compounds show effectiveness against the Omicron variant of COVID-19.

08:30 10 Jun 2023 ANIX

Anixa Biosciences Announces Notice of Allowance for Additional Patent on its CAR-T Cancer Therapy

SAN JOSE, Calif., Oct. 1, 2021 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX) ("Anixa"), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced today that the U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance broadening protection of Anixa's novel Chimeric Antigen Receptor-T cell (CAR-T) cancer treatment technology, known as its Chimeric Endocrine Receptor T-cell, or CER-T approach, or more specifically, "Follicle Stimulating Hormone Receptor-Mediated CAR-T technology," which has been licensed from The Wistar Institute and is being developed in partnership with Moffitt Cancer Center.

08:31 10 Jun 2023 ANIX

Anixa Biosciences' Ovarian Cancer CAR-T Therapy to be Discussed at Upcoming Emerging Immunotherapeutics for Ovarian Cancer Symposium

SAN JOSE, Calif., Sept. 14, 2021 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced today that the inventor of its ovarian cancer CAR-T technology, Dr. José Conejo-Garcia, Chair of the Immunology Department at Moffitt Cancer Center, will be presenting at the Antibody Society and Ovarian Cancer Research Alliance's Emerging Immunotherapeutics for Ovarian Cancer Symposium on September 23, 2021.

ANIX Financial details

Company Rating
Buy
Market Cap
105.76M
Income
-11.76M
Revenue
2.47B
Book val./share
0.9
Cash/share
0.9
Dividend
-
Dividend %
-
Employees
4
Optionable
No
Shortable
Yes
Earnings
10 Jun 2022
P/E
-8.99
Forward P/E
-
PEG
6.45
P/S
0.04
P/B
3.81
P/C
3.83
P/FCF
-14.52
Quick Ratio
22.6
Current Ratio
22.81
Debt / Equity
0.01
LT Debt / Equity
0.01
-
-
EPS (TTM)
-0.39
EPS next Y
-
EPS next Q
-
EPS this Y
-2.22%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-11.92%
Revenue last 5Y
366.92%
Revenue Q/Q
-
EPS Q/Q
-37.64%
-
-
-
-
SMA20
-12.27%
SMA50
-22.04%
SMA100
-24.83%
Inst Own
100%
Inst Trans
88.03%
ROA
-42%
ROE
-39%
ROC
-0.46%
Gross Margin
100%
Oper. Margin
-1%
Profit Margin
-
Payout
-
Shs Outstand
30.92M
Shs Float
29.52M
-
-
-
-
Target Price
8
52W Range
2.77-6.45
52W High
-42.61%
52W Low
+72.19%
RSI
44.55
Rel Volume
0.18
Avg Volume
98.38K
Volume
17.91K
Perf Week
12.54%
Perf Month
-15.8%
Perf Quarter
-17.02%
Perf Half Y
-29.58%
-
-
-
-
Beta
0.95109
-
-
Volatility
0.12%, 0.28%
Prev Close
-1.61%
Price
3.4437
Change
-0.76%

ANIX Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2022-10-31

Metric History 2018-10-312019-10-312020-10-312021-10-31 2022-10-31
Revenue per share
0.060.0100.0281.29
Net income per share
-0.83-0.63-0.46-0.45-0.44
Operating cash flow per share
-0.24-0.24-0.28-0.17-0.21
Free cash flow per share
-0.24-0.25-0.28-0.17-0.21
Cash per share
0.290.30.411.250.98
Book value per share
0.310.260.391.240.96
Tangible book value per share
0.250.240.371.220.93
Share holders equity per share
0.310.260.391.240.96
Interest debt per share
0000.010.01
Market cap
71.38M76.59M45.79M145.47M170.09M
Enterprise value
68.32M73.09M39.43M116.6M157.96M
P/E ratio
-4.9-6.17-4.45-11.24-12.61
Price to sales ratio
64.16306.350283.840.07
POCF ratio
-16.7-16.15-7.41-29.47-26.2
PFCF ratio
-16.55-15.58-7.4-29.47-26.2
P/B Ratio
13.1314.635.234.15.86
PTB ratio
13.1314.635.234.15.86
EV to sales
61.41292.380227.510.06
Enterprise value over EBITDA
-5.13-6.9-4.05-8.91-11.42
EV to operating cash flow
-15.99-15.42-6.38-23.62-24.33
EV to free cash flow
-15.85-14.87-6.37-23.62-24.33
Earnings yield
-0.2-0.16-0.22-0.09-0.08
Free cash flow yield
-0.06-0.06-0.14-0.03-0.04
Debt to equity
000.010.010.01
Debt to assets
000.010.010.01
Net debt to EBITDA
0.230.330.652.210.88
Current ratio
4.384.117.8828.3414.83
Interest coverage
0000-133.41
Income quality
0.30.40.610.380.47
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
6.2122.65013.80
Research and developement to revenue
6.1221.89012.080
Intangibles to total assets
0.130000
Capex to operating cash flow
0.010.04000
Capex to revenue
-0.03-0.7000
Capex to depreciation
-0.11-0.38-0.1800
Stock based compensation to revenue
822.85015.720
Graham number
2.41.932.033.553.09
ROIC
57.29.452.810.58-2.5
Return on tangible assets
-2.6-1.97-1.09-0.36-0.44
Graham Net
0.220.220.351.20.9
Working capital
4.27M4.61M8.18M34.73M28.16M
Tangible asset value
4.35M4.81M8.26M34.77M28.2M
Net current asset value
4.27M4.61M8.18M34.51M27.99M
Invested capital
000.010.010.01
Average receivables
033.26K34.38K1.12K0
Average payables
531.17K583.91K409.09K184.28K200.6K
Average inventory
00000
Days sales outstanding
097.13000
Days payables outstanding
276.461.29K0129.120
Days of inventory on hand
00000
Receivables turnover
03.76000
Payables turnover
1.320.2802.830
Inventory turnover
00000
ROE
-2.68-2.37-1.17-0.37-0.46
Capex per share
0-0.01000

Quarterly Fundamentals Overview

Last date of statement is 2023-01-31 for Q1

Metric History 2022-01-312022-04-302022-07-312022-10-31 2023-01-31
Revenue per share
00081.290
Net income per share
-0.13-0.12-0.09-0.11-0.07
Operating cash flow per share
-0.04-0.08-0.05-0.05-0.06
Free cash flow per share
-0.04-0.08-0.05-0.05-0.06
Cash per share
1.151.071.040.980.9
Book value per share
1.131.071.040.960.9
Tangible book value per share
1.11.041.010.930.87
Share holders equity per share
1.131.071.040.960.9
Interest debt per share
0.010.010.010.010.01
Market cap
98.81M97.99M118.15M170.09M135.12M
Enterprise value
69.28M70.5M94.13M157.96M125.54M
P/E ratio
-6.45-6.92-10.93-12.52-15.93
Price to sales ratio
0000.070
POCF ratio
-82.55-42.5-84.63-106.78-67.97
PFCF ratio
-82.55-42.5-84.63-106.78-67.97
P/B Ratio
2.913.053.735.864.86
PTB ratio
2.913.053.735.864.86
EV to sales
0000.060
Enterprise value over EBITDA
-17.9-19.7-33.77-43.9-49.33
EV to operating cash flow
-57.88-30.57-67.43-99.16-63.15
EV to free cash flow
-57.88-30.57-67.43-99.16-63.15
Earnings yield
-0.04-0.04-0.02-0.02-0.02
Free cash flow yield
-0.01-0.02-0.01-0.01-0.01
Debt to equity
0.010.010.010.010.01
Debt to assets
0.010.010.010.010.01
Net debt to EBITDA
7.637.688.623.373.76
Current ratio
19.5827.3922.0114.8322.81
Interest coverage
-3.88K-3.59K-127.14-45.11-12.65
Income quality
0.310.640.50.450.84
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
00000
Research and developement to revenue
00000
Intangibles to total assets
00000
Capex to operating cash flow
00000
Capex to revenue
00000
Capex to depreciation
00000
Stock based compensation to revenue
00000
Graham number
1.81.681.441.551.18
ROIC
0.150.160.17-0.64-0.27
Return on tangible assets
-0.11-0.11-0.08-0.11-0.07
Graham Net
1.081.020.990.90.85
Working capital
33.21M31.37M30.87M28.16M26.87M
Tangible asset value
33.24M31.41M30.91M28.2M26.91M
Net current asset value
33M31.17M30.68M27.99M26.71M
Invested capital
0.010.010.010.010.01
Average receivables
000073.5K
Average payables
320.1K298.5K160K246K187.5K
Average inventory
00000
Days sales outstanding
00000
Days payables outstanding
00000
Days of inventory on hand
00000
Receivables turnover
00000
Payables turnover
00000
Inventory turnover
00000
ROE
-0.11-0.11-0.09-0.12-0.08
Capex per share
00000

ANIX Frequently Asked Questions

What is Anixa Biosciences, Inc. stock symbol ?

Anixa Biosciences, Inc. is a US stock , located in San jose of Ca and trading under the symbol ANIX

Is Anixa Biosciences, Inc. buy or a sell ?

1 stock analysts have 1 predictions with a medium analyst target price of $8. The lowest prediction is $8 and the highest is $8

What is ANIX stock prediction ?

What is Anixa Biosciences, Inc. stock quote today ?

Anixa Biosciences, Inc. stock price is $3.4437 today.

Is Anixa Biosciences, Inc. stock public?

Yes, Anixa Biosciences, Inc. is a publicly traded company.

Something similar

Top by Market Cap
Top Correlated ETFs
Top Correlated Stocks
Similar Market Cap